[8-K] Amkor Technology Inc Reports Material Event

Rhea-AI Filing Summary

Liquidia Corporation (Nasdaq: LQDA) filed a Form 8-K announcing the appointment of Dana Boyle as Chief Accounting Officer effective July 1, 2025. Boyle, 41, has led the company’s accounting function since January 2021 as SVP-Finance and Controller. Her background includes senior finance roles at Aerami Therapeutics and Aralez Pharmaceuticals, plus public-accounting experience at Deloitte & Touche. She is a licensed CPA (NY) and holds a B.S. in Accounting from Rutgers University.

Compensation package:

• Annual base salary: $425,000
• Target cash bonus: 50 % of base salary
• Equity award: Restricted Stock Units valued at $300,000 on the effective date. Vesting schedule: 25 % on July 11, 2026; remaining 75 % in equal quarterly installments over the following three years, subject to continued employment.

Severance terms: Under the Amended & Restated Executive Severance and Change in Control Plan, Boyle is entitled to up to 12 months of salary continuation, COBRA premium payments, and—if terminated within a change-in-control period—accelerated vesting of 100 % of unvested equity plus target bonus payout.

The filing states that no family relationships or related-party transactions exist. The appointment was not made pursuant to any arrangement with other parties.

Investor take-away: While the event does not directly influence revenue or near-term financials, installing a seasoned CAO may enhance financial reporting quality and internal controls—an incremental positive for governance‐focused investors.

Insights

Financial Governance Analyst

TL;DR – Experienced CAO hired; improves accounting oversight, modestly positive governance signal.

The appointment of Dana Boyle consolidates Liquidia’s finance leadership under a credentialed CPA with both biotech and public-company expertise. Stable, competent accounting leadership is particularly important as Liquidia advances late-stage pulmonary hypertension programs that will add complexity to revenue recognition and R&D capitalization once commercialized. The equity-heavy compensation aligns Boyle’s incentives with shareholders over a multi-year horizon, and the severance framework is market-standard, containing double-trigger acceleration only in a change-in-control scenario. No red flags on related-party dealings or excessive payouts are evident. Overall impact is mildly positive for governance and internal-control risk profile, but not a catalyst for valuation in the near term.

Portfolio Manager – Small-Cap Biopharma

TL;DR – Neutral to portfolio returns; strengthens back-office, not thesis-shifting.

From an investment perspective, this 8-K is routine. A CAO transition rarely affects modelled cash flows or probability-of-success on drug candidates. The compensation levels are consistent with peers at similar market caps (<$1 bn), and the RSU vesting promotes retention through key regulatory milestones expected in the next three years. I see no change to risk-adjusted valuation or target price, but governance score ticks up slightly, which could marginally broaden the institutional investor base.

0001047127false00010471272025-06-272025-06-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

June 27, 2025

AMKOR TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-29472

23-1722724

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2045 EAST INNOVATION CIRCLE

TEMPE, AZ 85284

(Address of principal executive offices, including zip code)

(480) 821-5000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class			Trading Symbol			Name of Each Exchange on Which Registered
Common Stock, $0.001 par value			AMKR			The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 1.01. Entry into a Material Definitive Agreement.

The information provided in Item 2.03 below is hereby incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On June 27, 2025, Amkor Technology, Inc. (the “Company”) entered into the First Amendment to Credit Agreement (the “Amendment”), which amends the existing senior revolving credit facility, dated as of May 9, 2025 (the “Existing Credit Agreement” and, as amended by the Amendment, the “Credit Agreement”), by and among the Company, as borrower, the Lenders party thereto from time to time, the L/C Issuers party thereto and Bank of America, N.A., as administrative agent. The Amendment creates a new tranche of term loans, the Term A-1 Loans, which are secured and guaranteed on a pari passu basis to the revolver loans under the Existing Credit Agreement. The proceeds of the Term A-1 Loans will be used to refinance certain existing debt of the Company and for general corporate purposes. Capitalized terms used but not defined herein shall have the meaning ascribed to them in the Credit Agreement or the Amendment, as applicable.

The Term A-1 Loans have an aggregate principal amount of $500 million, will mature on May 9, 2030, and are subject to annual amortization of 2.5% of the original principal amount per year in 2026 and 2027 and 5% of the original principal amount per year thereafter, payable quarterly.

The Company may elect interest rates on its Term A-1 Loan borrowings calculated by reference to (x) Term SOFR or (y) a Base Rate plus a margin based on the Company’s consolidated leverage ratio.

The foregoing summary of the Amendment is not complete and is qualified in its entirety by the full text of the Amendment, a copy of which is included with this report as Exhibit 10.1 and incorporated by reference herein.

Item 8.01. Other Events.

On June 27, 2025, the Company notified U.S. Bank Trust Company, National Association, as trustee, that it will redeem $125 million aggregate principal amount 6.625% Senior Notes due 2027 (the “Notes”) at the redemption price, calculated in accordance with the indenture governing the Notes, plus accrued and unpaid interest. The redemption date for the Notes will be July 30, 2025. Following such redemption, $400 million aggregate principal amount of the Notes shall remain outstanding. This Current Report on Form 8-K is not a notice of redemption for the Notes.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit						Description
10.1						First Amendment to Credit Agreement, dated June 27, 2025, among Amkor Technology, Inc., as the Borrower, the Guarantors, the Non-Loan Party Equity Pledgor, the Term A-1 Lenders, the Revolving Lenders party thereto and Bank of America, N.A., as Administrative Agent.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMKOR TECHNOLOGY, INC.

By:

/s/ Mark N. Rogers

Mark N. Rogers

Executive Vice President, General Counsel, and Corporate Secretary

Date: July 1, 2025

FAQ

Who is Liquidia's new Chief Accounting Officer and when was she appointed?

Dana Boyle was appointed CAO effective July 1, 2025.

What is the base salary and bonus opportunity for LQDA's new CAO?

Boyle will earn a $425,000 base salary and is eligible for a 50 % annual cash bonus.

How many restricted stock units did Dana Boyle receive from Liquidia?

She received RSUs valued at $300,000 on the grant date, vesting over four years.

What severance benefits could the CAO receive upon termination?

She may receive 12 months of salary, COBRA premiums, and accelerated equity vesting if terminated during a change-in-control period.

Does the 8-K disclose any related-party transactions involving Ms. Boyle?

No. The filing states no direct or indirect material interests under Item 404(a).